alpha-aminopyridine has been researched along with an2728 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chat, VS; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
| Lé, AM; Torres, T | 1 |
2 review(s) available for alpha-aminopyridine and an2728
| Article | Year |
|---|---|
Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dermatitis, Atopic; Dermatologic Agents; Humans; Nitriles; Pyrazoles; Pyrimidines; Resorcinols; Severity of Illness Index; Skin Cream; Stilbenes; Treatment Outcome | 2020 |
New Topical Therapies for Psoriasis.
Topics: Administration, Topical; Aminopyridines; Amygdalin; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dermatologic Agents; Humans; Interleukin-2; MicroRNAs; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrazoles; Pyrimidines; Resorcinols; Stilbenes | 2022 |
1 other study(ies) available for alpha-aminopyridine and an2728
| Article | Year |
|---|---|
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |